Drug Characteristics
  • Formulation

    Tablets: 250mg and 500mg

    IV infusion: 5mg/ml, 100ml infusion bag (to be given over at least 60 minutes)

  • Dose

    Community acquired pneumonia: 

    500mg once of twice daily for 7-14 days

    Skin and soft tissue infections: 

    500mg once of twice daily for 7-14 days

    UTI (complicated): 

    500mg once daily for 7-14 days

    Chronic prostatitis: 

    500mg once daily for 28 days

  • Side Effects

    Gastrointestinal disturbances, CNS effects (dizziness, headache, insomnia, fitting, euphoria – use in caution in patients with epilepsy), transient increases in LFTs, rash, taste disturbances, transient increases in serum creatinine and urea. Tendon damage (CSM warning) and severe anaphylaxis (rare).

  • Interactions

    No significant interactions with ART expected

  • Renal

    eGFR 20-50: half normal dose

    eGFR <20: seek specialist advice

  • Hepatic

    No dose adjustment necessary

  • Pregnancy

    Avoid in pregnancy (arthropathy in animal studies). Safer alternatives generally available.

    Breast feeding: manufacturer advises avoid

  • Other Information

    Tendon rupture/damage has been reported in patients receiving quinolones. 

    May impair performance of skilled tasks (e.g driving)